论文部分内容阅读
目的观察吉非替尼二线或二线以上方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法126例晚期NSCLC患者口服吉非替尼250mg/天,直到疾病进展或不可耐受的毒副反应停药。结果126例患者,总有效率为30.1%(38/126),疾病控制率为81.7%(103/126)。有效患者中位缓解时间为6.6个月,全组中位肿瘤进展时间(TTP)为4.9个月,中位总生存时间为9.8个月,1年生存率为38.2%。腺癌患者有效率、生存时间及TTP均显著高于鳞癌患者,女性患者有效率和生存时间优于男性患者。脑转移患者有效率为50%。主要毒副反应为皮疹和腹泻,皮疹发生率最高(47.6%),但多数较轻并可逆。结论吉非替尼作为二线及二线以上方案治疗晚期NSCLC安全有效,易为患者接受。
Objective To observe the clinical efficacy of gefitinib in second-line or second-line treatment of advanced non-small cell lung cancer (NSCLC). Methods 126 patients with advanced NSCLC were treated with gefitinib 250 mg once daily until disease progression or intolerable side effects were discontinued. Results In 126 patients, the total effective rate was 30.1% (38/126) and the disease control rate was 81.7% (103/126). The median effective response time was 6.6 months, the median overall tumor progression time (TTP) was 4.9 months, the median overall survival time was 9.8 months and the 1-year survival rate was 38.2%. The effective rate, survival time and TTP in patients with adenocarcinoma were significantly higher than those in patients with squamous cell carcinoma. The female patients had better efficiency and survival time than male patients. The effective rate of brain metastases is 50%. The main side effects were rash and diarrhea with the highest incidence of rash (47.6%), but most were mild and reversible. Conclusion Gefitinib is safe and effective as a second-line and second-line treatment for advanced NSCLC and is easy for patients to accept.